Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

Market Cap

$116.62M

MomentumView details →

1D Return

−7.00%

YTD Return

−58.75%

RSI (14)

41.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

Market Cap

$116.62M

RSI (14)

41.0

MomentumView details →

1D Return

−7.00%

YTD Return

−58.75%

SummaryUpdated Jun 1, 2026

Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in San Diego, California. The company specializes in developing innovative small-molecule therapeutics that target the body's natural homeostatic pathways to treat metabolic diseases. Since its incorporation, Aardvark has focused on addressing rare metabolic disorders through a novel approach of activating bitter taste receptors in the gastrointestinal tract, representing a unique therapeutic strategy in the biotechnology sector.

Ask drillr about Aardvark Therapeutics, Inc. Common Stock →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−93.44%

ROA (TTM)

−85.80%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−53.59%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−82.92%

EarningsView details →

EPS (Actual)

−$0.66

EPS Surprise

24.52%

Beats (12Q)

3/12

Next Q EPS Est

−$0.72

Avg Surprise (4Q)

5.34%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

12.63x

Quick Ratio

12.63x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−69.89M

Op. CF (TTM)

−69.41M

Next earningsNov 12, 2026 →

Latest newsMore news →

A lawsuit was filed against Aardvark Therapeutics, Inc. on behalf of certain investors who purchased shares between February 13, 2025 and May 14, 2026, with a deadline of October 31, 2026 for investors to act.15d ago

Hagens Berman Sobol Shapiro LLP notified investors of a pending securities class action lawsuit against Aardvark Therapeutics, Inc. related to its IPO and subsequent securities purchases.15d ago

Similar companies

Nautilus Biotechnology, Inc.NAUT Connect Biopharma Holdings LimitedCNTB Vaxart, Inc.VXRT ProMIS Neurosciences, Inc.PMN Genelux CorporationGNLX enGene Holdings Inc.ENGN Find similar companies →

Latest newsMore news →

A lawsuit was filed against Aardvark Therapeutics, Inc. on behalf of certain investors who purchased shares between February 13, 2025 and May 14, 2026, with a deadline of October 31, 2026 for investors to act.15d ago Hagens Berman Sobol Shapiro LLP notified investors of a pending securities class action lawsuit against Aardvark Therapeutics, Inc. related to its IPO and subsequent securities purchases.15d ago A class action lawsuit was filed against Aardvark Therapeutics, Inc. alleging the company misled investors about the viability and efficacy of its lead drug candidate ARD-101, covering purchasers of its IPO stock and securities during the Class Period from February 13, 2025 to May 14, 2026.21d ago